What is FTH's market cap?

$516.55M, based on the Nov 4 close of $19.99.

Does Faeth Therapeutics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of FTH is sold short?

2.3M shares, 20.5% of float, as of Oct 15, 2026.

What sector is FTH in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · FTHHealthcarePharmaceuticals

Faeth Therapeutics, Inc. Common Stock (FTH)

$19.99+1.73%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$19.99▼ 46.61% in range

Sep 11, 2026Low $16.83 · High $39.09Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Faeth Therapeutics closed at $19.99 on Nov 4, up 1.73%, 48.9% below its highest close since Sep 11. Volume of 237.1K shares was 0.64× its 20-day average (below normal).

Split-adjusted performance: -25.7% over one month.

Short interest was 2.3M shares at the Oct 15 settlement, up 12.2% from the prior report (20.5% of float, 7.8 days to cover).

Market cap$516.6M25.8M shares

Revenue · quarter$0.00—

Diluted EPS$-0.79—

P/E · TTM—

Net margin—

Dividend yieldNone

Range since Sep 1116.83 – 39.09−48.9% from high

Volume237.1K0.64× 20-day avg

Volatility · 60d—Annualised

Short % of float20.5%7.8 days to cover

Net cash$174.8MCash $174.8M

Next earnings—Not scheduled

Split-adjusted performance

1W +4.1%1M −25.7%3M —6M —YTD —1Y —3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum—

Revenue growth—

Net margin—

Value (low P/E)—

Size61

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short2.3M+12.3% vs prior

Days to cover7.8Settled Oct 15

% of float20.5%

Short vol. 10d64.2%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
FTHFaeth Therapeutics	$19.99	+1.73%	—	—	—	—	$516.6M
STTKShattuck Labs	$5.15	−5.85%	−22.9%	—	—	—	$516.9M	Compare
CAPRCapricor Therapeutics	$8.92	+8.25%	−74.1%	—	—	—	$518.6M	Compare
CBIOCrescent Biopharma	$13.82	+5.82%	−23.5%	—	—	—	$513.4M	Compare
CTMXCytomX Therapeutics	$2.35	+7.80%	−43.1%	−92.4%	−1457.4%	—	$512.1M	Compare
OVIDOvid Therapeutics	$2.74	+14.17%	−1.4%	−88.3%	−2047.6%	—	$535.1M	Compare
CLYMClimb Bio	$9.33	−4.31%	−23.6%	—	—	—	$535.9M	Compare
EOLSEvolus	$7.47	+1.36%	+18.2%	+21.2%	−9.6%	—	$493.4M	Compare
MNPRMonopar Therapeutics	$72.81	+4.18%	+14.0%	—	—	—	$488.7M	Compare

News about Faeth Therapeutics

All news →

No recent articles focused on Faeth Therapeutics. 1 articles mention it in passing.

Quick answers

What does Faeth Therapeutics do?: Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
What is FTH's market cap?: $516.55M, based on the Nov 4 close of $19.99.
Does Faeth Therapeutics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of FTH is sold short?: 2.3M shares, 20.5% of float, as of Oct 15, 2026.
What sector is FTH in?: Healthcare, in the Pharmaceuticals industry.

About Faeth Therapeutics

Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.

HQ: Austin, TX29 employeesListed Feb 4, 2021faeththerapeutics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology